Merck upbeat despite drop in profit
German chemical and pharmaceutical group Merck KGaA on Monday reported a sharp slump in quarterly net profit, but forecast higher earnings from its chemicals units and unveiled its first site in China.
Merck said its third quarter net profit fell by 26.8 percent from the same period a year earlier to €148.1 million ($223 million), owing to poor results in liquid crystal production units and chemical divisions in general.
Sales gained 2.7 percent meanwhile to €1.94 billion. The company said earnings should now begin to pick up as well.
"Even in our chemical businesses, which were substantially impacted by the economic crisis, we see a clear trend toward recovery," Merck chairman Karl-Ludwig Kley was quoted as saying.
He told a telephone news conference that Merck had bought the pigment producer Taizhu, giving the German company "an initial production point in China."
Merck would reduce the number of workers on state-subsidised shorter working hours and expected to eliminate use of the programme by the end of the year, Kley added.
In the group's pharmaceutical branch, sales gained 5.8 percent in the third quarter to €1.313 billion, in large part owing to stronger demand for the multiple sclerosis treatment Rebif, cancer drug Erbitux and fertility treatment Gonal-f.
For the full year, Merck forecast sales growth of around two percent.
Comments
See Also
Merck said its third quarter net profit fell by 26.8 percent from the same period a year earlier to €148.1 million ($223 million), owing to poor results in liquid crystal production units and chemical divisions in general.
Sales gained 2.7 percent meanwhile to €1.94 billion. The company said earnings should now begin to pick up as well.
"Even in our chemical businesses, which were substantially impacted by the economic crisis, we see a clear trend toward recovery," Merck chairman Karl-Ludwig Kley was quoted as saying.
He told a telephone news conference that Merck had bought the pigment producer Taizhu, giving the German company "an initial production point in China."
Merck would reduce the number of workers on state-subsidised shorter working hours and expected to eliminate use of the programme by the end of the year, Kley added.
In the group's pharmaceutical branch, sales gained 5.8 percent in the third quarter to €1.313 billion, in large part owing to stronger demand for the multiple sclerosis treatment Rebif, cancer drug Erbitux and fertility treatment Gonal-f.
For the full year, Merck forecast sales growth of around two percent.
Join the conversation in our comments section below. Share your own views and experience and if you have a question or suggestion for our journalists then email us at [email protected].
Please keep comments civil, constructive and on topic – and make sure to read our terms of use before getting involved.
Please log in here to leave a comment.